Will Johnson & Johnson Be a Better Buy After Spinning Off Its Consumer Business?

Johnson & Johnson (NYSE: JNJ) announced last year that it would be spinning off its consumer health business. Let's take a closer look at whether the spinoff is a good move for the business, why the company is likely doing it, and if investors will be better off in the long run. Johnson & Johnson management says that hiving off its consumer health business into a new, publicly traded entity will leave the remaining operations better-positioned to serve patients and consumers, and give it the ability to "pursue more targeted business strategies and accelerate growth."